Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS)
CNY16.89
-0.08 (-0.47%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
Xunqiao 317024
Linhai, CN
Linhai, CN
CEO
Bao Hua Chen
Website
huahaipharm.com
IPO
2003-03-04
ISIN CNE000001DL5
Description
Zhejiang Huahai Pharmaceutical Co., Ltd. is a China-based pharmaceutical enterprise with a global presence. Its diverse portfolio encompasses treatments for central nervous system disorders, cardiovascular conditions, and viral infections, among other finished pharmaceutical products. Beyond finished drugs, the company also produces Active Pharmaceutical Ingredients (APIs) and crucial intermediates. Huahai Pharmaceutical further engages in the manufacturing of packaging components, notably high-density polyethylene (HDPE) bottles and polypropylene (PP) caps. Additionally, it offers contract manufacturing (CMO) and other specialized services, while also playing a role in import and export trade services. Established in 1989, the company maintains its headquarters in Linhai, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY16.89
-0.08 (-0.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
25M
Beta
0.18
Float Shares
892.08M
Free Float %
59.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.82% | +3.99% | +7.01% | +7.89% | -10.27% | -0.12% | +18.12% | -7.43% | -17.24% | +0.12% | +1,093.66% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
16.89
Ratings Trend (MoM)
91% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.06
Grey zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-10.6% Q1'26: -1.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-76.6% Q1'26: +28.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.8% Q1'26: -2.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.6% Q1'26: +11.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.1% Q1'26: +5.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+2.1% Q1'26: +5.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.44× Q1'26: 8.88× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.50B
est: 3.32B (+5.5%)
|
4.09B
est: 4.21B (-2.8%)
|
5.00B
est: 4.93B (+1.4%)
|
5.09B
est: 5.17B (-1.4%)
|
5.39B
est: 5.40B (-0.3%)
|
6.49B
est: 6.67B (-2.7%)
|
6.64B
est: 6.19B (+7.3%)
|
8.27B
est: 8.48B (-2.5%)
|
8.31B
est: 9.14B (-9.1%)
|
9.55B
est: 9.74B (-1.9%)
|
8.54B
est: 8.46B (+0.9%)
|
9.17B
8.87B – 9.47B
+8.3% YoY
|
9.99B
9.37B – 10.62B
+9.0% YoY
|
11.13B
10.62B – 11.64B
+11.4% YoY
|
| EBITDA |
681.64M
est: 818.46M (-16.7%)
|
750.33M
est: 1.04B (-27.7%)
|
1.14B
est: 1.22B (-6.3%)
|
700.81M
est: 1.27B (-45.0%)
|
1.24B
est: 1.33B (-7.0%)
|
1.85B
est: 1.64B (+12.3%)
|
1.05B
est: 1.53B (-31.2%)
|
2.23B
est: 2.09B (+6.6%)
|
2.14B
est: 2.08B (+3.1%)
|
2.51B
est: 2.21B (+13.6%)
|
1.59B
est: 1.92B (-17.1%)
|
2.08B
2.01B – 2.15B
+8.3% YoY
|
2.27B
2.13B – 2.41B
+9.0% YoY
|
2.53B
2.41B – 2.64B
+11.4% YoY
|
| EBIT |
484.09M
est: 539.23M (-10.2%)
|
499.38M
est: 683.97M (-27.0%)
|
850.37M
est: 801.55M (+6.1%)
|
355.77M
est: 839.33M (-57.6%)
|
828.28M
est: 877.98M (-5.7%)
|
1.38B
est: 1.08B (+26.9%)
|
502.48M
est: 1.01B (-50.1%)
|
1.58B
est: 1.38B (+14.5%)
|
1.36B
est: 1.22B (+11.6%)
|
1.62B
est: 1.30B (+25.1%)
|
567.17M
est: 1.13B (-49.7%)
|
1.22B
1.18B – 1.26B
+8.3% YoY
|
1.33B
1.25B – 1.42B
+9.0% YoY
|
1.48B
1.42B – 1.55B
+11.4% YoY
|
| Net Income |
442.47M
est: 487.67M (-9.3%)
|
500.83M
est: 558.07M (-10.3%)
|
639.25M
est: 662.77M (-3.5%)
|
107.51M
est: 593.07M (-81.9%)
|
569.60M
est: 691.81M (-17.7%)
|
929.82M
est: 1.15B (-19.0%)
|
487.54M
est: 664.66M (-26.6%)
|
1.17B
est: 1.13B (+3.0%)
|
830.47M
est: 1.01B (-17.8%)
|
1.12B
est: 1.26B (-11.0%)
|
266.94M
est: 291.67M (-8.5%)
|
939.24M
898.81M – 979.67M
+222.0% YoY
|
1.18B
422.10M – 1.62B
+25.2% YoY
|
1.54B
800.83M – 2.30B
+31.0% YoY
|
| SGA |
1.14B
est: 1.09B (+5.1%)
|
1.47B
est: 1.38B (+6.5%)
|
1.55B
est: 1.61B (-3.9%)
|
2.13B
est: 1.69B (+26.2%)
|
1.86B
est: 1.77B (+4.9%)
|
2.08B
est: 2.18B (-4.7%)
|
2.45B
est: 2.03B (+20.7%)
|
2.53B
est: 2.78B (-8.7%)
|
2.59B
est: 2.86B (-9.3%)
|
3.14B
est: 3.04B (+3.3%)
|
2.11B
est: 2.65B (-20.4%)
|
2.87B
2.77B – 2.96B
+8.3% YoY
|
3.12B
2.93B – 3.32B
+9.0% YoY
|
3.48B
3.32B – 3.64B
+11.4% YoY
|
| EPS |
0.33
est: 0.34 (-2.8%)
|
0.37
est: 0.38 (-3.7%)
|
0.47
est: 0.46 (+2.4%)
|
0.08
est: 0.41 (-80.0%)
|
0.39
est: 0.48 (-18.1%)
|
0.64
est: 0.79 (-19.0%)
|
0.34
est: 0.46 (-26.6%)
|
0.81
est: 0.78 (+3.8%)
|
0.57
est: 0.70 (-18.5%)
|
0.77
est: 0.85 (-9.1%)
|
0.18
est: 0.20 (-8.5%)
|
0.63
0.61 – 0.66
+222.0% YoY
|
0.69
0.28 – 1.10
+8.9% YoY
|
1.05
0.54 – 1.55
+51.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.36B
OE per share TTM
-0.92
Owner's Yield
-5.36%
Maintenance CapEx ratio
117.77%
Maint CapEx / Avg PPE
89.3%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 37 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.17% | 61.9K | 0.65% |
| 2 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.04% | 7.1K | 0.65% |
| 3 | WisdomTree Emerging Markets SmallCap Dividend Fund DGS | 0.04% | 688.8K | 0.58% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.04% | 28.1K | 0.55% |
| 5 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 8.4K | 0.15% |
| 6 | Franklin FTSE China ETF FLCH | 0.01% | 32.8K | 0.19% |
| 7 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 138.5K | 0.19% |
| 8 | Franklin FTSE Asia ex Japan ETF FLAX | 0.00% | 1.7K | 0.19% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 251.2K | 0.39% |
| 10 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 346.1K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
69.0K
Shares Outstanding
1.50B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bao Hua Chen | GM, President & Director | — | male |
| Bin He | Vice President | — | male |
| Bo Xu | Vice President | — | male |
| Lihong Lin | Vice President | — | female |
| Mei Zhang | Senior Vice President & Chief Financial Officer | — | female |
| Mi Xu | Vice President | — | female |
| Qi Mao Chen | Vice President | — | male |
| Sijia Guo | Executive Vice President & Director | — | male |
| Yanhua Meng | Vice President | — | female |
| Yong Hua Zhu | Vice President, Secretary of the Board & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600521.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
